WLLW

WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC

Retrieved on: 
Thursday, February 29, 2024
AB, WLLW, TSX, Toronto Stock Exchange, Warrant, Food, Indian stock exchange, Willow, Acceleration, Legislation, Security (finance)

CALGARY, AB, Feb. 29, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the "Milestone Investment"), by way of non-brokered private placement, from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.

Key Points: 
  • CALGARY, AB, Feb. 29, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the "Milestone Investment"), by way of non-brokered private placement, from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.
  • This Milestone Investment is connected to the Kalsec investment announced by the Company on February 20, 2024, pursuant to which Kalsec committed to subscribe for an additional US$100,000.00 on the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria (the "Milestone").
  • Proceeds from the Milestone Investment will be used for the commercialization and development of the Company's pipeline of products, including natural food ingredients, working capital, and general corporate purposes.
  • All securities issued under the Milestone Investment, including securities issuable on exercise thereof, are subject to a hold period in Canada of four months and one day in accordance with applicable securities legislation.

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Retrieved on: 
Tuesday, February 20, 2024
AB, WLLW, TSX, Toronto Stock Exchange, Warrant, Food, Indian stock exchange, Funding, Acceleration, Legislation, Partnership, Security (finance)

CALGARY, AB, Feb. 20, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a strategic investment from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.

Key Points: 
  • CALGARY, AB, Feb. 20, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a strategic investment from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.
  • Proceeds from the Financing will be used for the commercialization and development of the Company's pipeline of products, including natural food ingredients, working capital, and general corporate purposes.
  • "We are delighted to expand our partnership with Kalsec to help bring the best products possible to Kalsec's customers with a keen focus on market-leading innovation and sustainability."
  • If the Milestone is achieved, the Company will issue a press release confirming details of the Additional Investment.

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Active ingredient, TSX, Health, API, WLLW, Willow, Fine chemical

The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale.

Key Points: 
  • The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale.
  • The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets.
  • "We are excited to once again apply our technology platform to the manufacture of more sustainable APIs for existing, large volume global markets," said Dr. Chris Savile, Willow's President & CEO.
  • This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Retrieved on: 
Tuesday, January 16, 2024
WLLW, TSX, API, Pharmaceutical industry

SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).

Key Points: 
  • SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
  • Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes.
  • The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale.
  • "If successful, we believe the developed biobased route will be more sustainable, cost effective and ensure access to these potentially life-changing medicines in Enterin's development pipeline."

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Retrieved on: 
Wednesday, January 10, 2024
Budesonide, WLLW, DNA, Partnership, API, Outline, TSX, Acceleration, Enzyme, Hydrocortisone, HTP, UDCA, CDMO, Prednisolone, Growth, Fine chemical

"2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.

Key Points: 
  • "2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.
  • We also generated record revenue growth through partnerships and implemented a successful corporate and operational reorganization to support the future growth of Willow," said Dr. Chris Savile, Willow's President & CEO.
  • Record revenues in 2023: Revenues increased approximately 60% to an estimated $1.3 million in 2023.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Retrieved on: 
Thursday, December 7, 2023
R, Willow, WLLW, API, TSX, Willow Garage, Fine chemical

SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.

Key Points: 
  • SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.
  • The parties' phase one feasibility program that applied Willow's BioOxi™ platform exceeded expectations and the partner has now agreed to continue full development toward commercialization, including additional R&D and scale-up work.
  • "We appreciate the trust our partner has in Willow to develop sustainable manufacturing routes to APIs and are delighted to continue to work with them to further develop and supply key advanced intermediates to support their development pipeline," said Dr. Chris Savile, Willow's President & CEO.
  • "This is truly an exciting time for Willow and the BioOxi platform as we rapidly move from R&D to manufacturing and supply in 2024."

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Retrieved on: 
Tuesday, November 14, 2023
UDCA, Research, Commercial, Bank statement, WLLW, Willow Garage, Steroid, API, Partnership, Ursodeoxycholic acid, R, TSX, Patent, Pharmaceutical industry, Fine chemical, Renewable energy, Video game, Willow, Q4

On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.

Key Points: 
  • On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.
  • On October 24, 2023, Aurora Cannabis Inc. and Willow announced a confidential settlement resolving the ongoing patent ligation in Canada.
  • Willow ended the quarter with approximately $4.0 million in cash as of September 30, 2023, plus receivables of over $0.6 million.
  • On September 12, 2023, Willow announced an insider led convertible debenture financing, which was closed on October 10, 2023 for gross proceeds of $0.8 million.

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING

Retrieved on: 
Wednesday, October 11, 2023
TSX, WLLW, Warrant, Finance Secretary (India), AB, Toronto Stock Exchange, Legislation, VWAP, MI, Minority, Acceleration, Offering, Security (finance), Share (finance)

CALGARY, AB, Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering").

Key Points: 
  • CALGARY, AB, Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering").
  • The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of C$515,000.
  • Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of C$1,000 (each, a "Convertible Debenture") with a maturity date of October 10, 2026 (the "Maturity Date") and 4,762 common share purchase warrants (each, a "Warrant").
  • The Convertible Debentures are convertible at the holder's option into Shares at any time prior to the earlier of the business day immediately preceding the Maturity Date and the date fixed for redemption of the Convertible Debentures at a conversion price of C$0.105 per Share.

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Retrieved on: 
Tuesday, October 3, 2023
Transfer, Immortalised cell line, GMP, Pharma, Partnership, Technology transfer, TT, API, Health, Fermentation, Active ingredient, Willow, Willow Garage, TSX, WLLW, Industrial, Food, Wellness, Fine chemical

SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ - Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.

Key Points: 
  • SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ - Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.
  • Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
  • SUANFARMA has engaged Willow to apply its strain engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA's manufacturing site.
  • SUANFARMA CDMO offers a comprehensive approach to Technology Transfer, aiming to reduce risks and enhance success within their global project management strategy.

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Retrieved on: 
Tuesday, October 3, 2023
Transfer, Immortalised cell line, GMP, Pharma, Partnership, Technology transfer, TT, API, Health, Fermentation, Active ingredient, Willow Garage, TSX, WLLW, Industrial, Food, Willow, Wellness, Fine chemical

SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ -- Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.

Key Points: 
  • SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ -- Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.
  • Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
  • SUANFARMA has engaged Willow to apply its strain engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA's manufacturing site.
  • SUANFARMA CDMO offers a comprehensive approach to Technology Transfer, aiming to reduce risks and enhance success within their global project management strategy.